Drug
Darunavir clinical trials
Also written Prezista, DRV and TMC114.
- studies test it
- 96
- open now
- 3
- in phase 3
- 27
- first study started
- 2001
Keep track of what changes. Save the Darunavir studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
96 studies that test it; most in 2008 (12)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2003 | 2 |
| 2005 | 2 |
| 2006 | 4 |
| 2007 | 5 |
| 2008 | 12 |
| 2009 | 10 |
| 2010 | 5 |
| 2011 | 9 |
| 2012 | 7 |
| 2013 | 2 |
| 2014 | 6 |
| 2015 | 7 |
| 2016 | 2 |
| 2017 | 5 |
| 2018 | 2 |
| 2019 | 5 |
| 2020 | 2 |
| 2021 | 4 |
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 31
- Phase 2
- 17
- Phase 3
- 27
- Phase 4
- 22
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 56 · Other 40
Tibotec Pharmaceuticals, Ireland (15) · Gilead Sciences (6) · Janssen Sciences Ireland UC (5) · St Stephens Aids Trust (5) · Tibotec, Inc (5) · Janssen Research & Development, LLC (4) · ANRS, Emerging Infectious Diseases (3) · Kirby Institute (3)
Often tested with
Tested in the same studies.
Ritonavir (45) · Cobicistat (22) · Emtricitabine (17) · Tenofovir alafenamide (13) · Etravirine (11) · Atazanavir (10) · Dolutegravir (8) · Raltegravir (6)
Studies
Open first, then newest update. How each study uses Darunavir is read from its arms, and is right about nine times in ten.
Testing it · 96
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV TreatmentsRecruitingPhase 4Gilead SciencesNCT06337032Written as DRV
- An Adaptive Platform Trial for Evaluation of Novel Treatment Regimens in Children and Adolescents With HIV in AfricaNot yet recruitingPhase 3University College, LondonNCT07792096Written as Darunavir (DRV)
- Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Compared With Darunavir/Cobicistat Plus Tenofovir Alafenamide/Emtricitabine in Virologically Suppressed People Living With HIV at 24 and 48 Weeks of Follow-upRecruitingPhase 4Instituto Mexicano del Seguro SocialNCT07678268Written as Dual therapy: darunavir/cobicistat + lamivudine
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIVActive, not recruitingPhase 2/3Gilead SciencesNCT02016924Written as DRV
- Study Comparing Efficacy and Safety of Darunavir Boosted With Ritonavir to HART With 2 NRTI and Darunavir Boosted With Ritonavir in HIV-1 Infected Patients ANRS136CompletedPhase 3French National Agency for Research on AIDS and Viral HepatitisNCT00421551Written as Darunavir
- Evaluation of a Dose Reduction of Darunavir (400 mg/d) in Virologically Suppressed HIV-1 PatientsCompletedPhase 2ANRS, Emerging Infectious DiseasesNCT02384967Written as Darunavir
- A Bioequivalence Study of Darunavir, Emtricitabine, and Tenofovir Alafenamide, in the Presence of Cobicistat in Healthy ParticipantsCompletedPhase 1Janssen Sciences Ireland UCNCT02578550Written as Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide fixed-dose combination (FDC)
- Study to Evaluate the Relative Bioavailability of Fixed-dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) as a Whole Tablet, as a Split Tablet, and as Crushed Tablet in Healthy Adult ParticipantsCompletedPhase 1Janssen Scientific Affairs, LLCNCT02984852Written as Darunavir (DRV)
- A Study of Darunavir in Combination With Cobicistat or Ritonavir, and Dabigatran Etexilate in Healthy ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT04208061Written as Darunavir
- A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat as Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared With Co-administration of the Separate AgentsCompletedPhase 1Janssen Research & Development, LLCNCT04661397Written as Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC
- A Study of Darunavir in the Presence of Cobicistat When Administered as a Fixed Dose Combination Under Fed ConditionsCompletedPhase 1Janssen Research & Development, LLCNCT04718805Written as Darunavir
- Body Composition Sub-study of the D2EFT TrialCompletedPhase 4Kirby InstituteNCT03675815Written as Darunavir (DRV) 800 milligram (MG) Oral Tablet
- Bioequivalence Study of GP30101 800 mg (GEROPHARM) Versus PREZISTA® 800 mg ("Jonson&Jonson", Russia)CompletedNot applicableGeropharmNCT04268472Written as Prezista®
- Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. (ReSTART)CompletedPhase 4The Crofoot Research Center, Inc.NCT04388904Written as Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC)
- HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS)CompletedPhase 1National Institute of Neurological Disorders and Stroke (NINDS)NCT02437110Written as Darunavir
- Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI BackboneWithdrawnPhase 3Bristol-Myers SquibbNCT01605084Written as Darunavir
- Dolutegravir and Darunavir Evaluation in Adults Failing TherapyStatus unknownPhase 4Kirby InstituteNCT03017872Written as Darunavir
- TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRVCompletedPhase 3Janssen Sciences Ireland UCNCT01281813Written as Darunavir
- A Study of Darunavir in the Presence of Cobicistat When Administered as a Fixed Dose Combination Compared to the Co-administration of the Separate Available Formulations of Darunavir and Cobicistat Under Fed Conditions in Healthy ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT05378906Written as DRV
- A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected SubjectsCompletedPhase 3Janssen Sciences Ireland UCNCT02431247Written as Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC
See all 96 studies that test Darunavir →
Given in every arm · 8 — Darunavir is usual care beside what is tested
- Bone, Immunologic, and Virologic Effects of a Antiretroviral RegimenCompletedPhase 2Advancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsNCT01400412Written as Darunavir
- Dual Therapy With Boosted Darunavir + DolutegravirCompletedPhase 3Technical University of MunichNCT02486133Written as Prezista
- Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV InfectionCompletedPhase 1/2SEARCH Research FoundationNCT02475915Written as Darunavir
- Study to Evaluate the Efficacy of GS-9131 Functional Monotherapy in Human Immunodeficiency Virus (HIV)-1-Infected Adults Failing a Nucleos(t)Ide Reverse Transcriptase Inhibitor-Containing Regimen With Nucleos(t)Ide Reverse Transcriptase Inhibitor Resistant VirusTerminatedPhase 2Gilead SciencesNCT03472326Written as DRV
- Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01)CompletedNot applicableRockefeller UniversityNCT00525733Written as darunavir 800 mg
- Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.CompletedPhase 1/2Gilead SciencesNCT01565889Written as DRV
- Raltegravir And Darunavir Antiretroviral in Antiretroviral Naive PatientsCompletedPhase 4Dallas VA Medical CenterNCT00677300Written as Darunavir
- A Study to Compare Brachial Artery Reactivity and Cardiovascular Risk of a Treatment Simplification by Darunavir/Ritonavir (DRV/r) 800/100 mg Versus a Triple Combination Therapy Containing DRV/r in HIV-1 Infected PatientsCompletedPhase 2Janssen-Cilag S.p.A.NCT01391013Written as Darunavir(DRV)
As the comparator · 8 — what is tested is compared with Darunavir
- Ndovu RCT: Investing the Optimal Management of Dolutegravir ResistanceRecruitingPhase 3University of NairobiNCT06747507Written as Darunavir+Ritonavir
- Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV NaiveWithdrawnPhase 4Juan A. ArnaizNCT02470650Written as Darunavir
- Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)CompletedPhase 3Merck Sharp & Dohme LLCNCT02275780Written as Darunavir
- A Prospective, Open-label Trial of Two ABC/3TC Based Regimens in Late Presenter naïve Patients (CD4 <200 Cells/µL)CompletedPhase 3University of Modena and Reggio EmiliaNCT01900106Written as abacavir/lamivudine + darunavir/ritonavir
- Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)TerminatedPhase 2Merck Sharp & Dohme LLCNCT02116660Written as Darunavir
- Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive SubjectsCompletedPhase 3ViiV HealthcareNCT01449929Written as darunavir 800mg OAD
- D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive AdultsCompletedPhase 2Gilead SciencesNCT01565850Written as DRV
- Effects of Steady State Tipranavir/Ritonavir or Darunavir/Ritonavir or Ritonavir on Platelet Function, Coagulation and Fibrinolysis Biomarkers in Healthy SubjectsCompletedPhase 1Boehringer IngelheimNCT02251795Written as Darunavir
Codes
What other systems call Darunavir · ClinicalTrials.gg INT006585
- MeSH (NLM) D000069454DarunavirConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) YO603Y8113DARUNAVIRConfirmed FDA, NLM, Wikidata
- RxNorm 460132Confirmed FDA, Wikidata
- Wikidata Q3765251darunavirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C65364DarunavirOne source FDA
- DrugBank DB01264One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000069454 | Darunavir | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | YO603Y8113 | DARUNAVIR | Confirmed FDA, NLM, Wikidata |
| RxNorm | 460132 | — | Confirmed FDA, Wikidata |
| Wikidata | Q3765251 | darunavir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C65364 | Darunavir | One source FDA |
| DrugBank | DB01264 | — | One source Wikidata |
Also registered as darunavir ethanolate (UNII 33O78XF0BW · RxNorm 644682).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.